You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Herantis Pharma: Disease-modifying drug for Parkinson’s
We have initiated coverage of Herantis Pharma, a drug development company focused on neurodegenerative diseases. In this interview analyst Antti Siltanen sheds light on what the company does, what its drug candidate HER-096 is all about, competing drug candidates and other pressing questions regarding the company.
Content:
00:00 Intro
00:16 What does Herantis do?
00:52 How does HER-096 work?
01:20 Risks
03:19 Competing drug candidates
04:57 Capital adequacy and funding options
06:23 Probability of commercialization
07:12 When to expect profit generation?
Nanoform, Audiocast with teleconference, Q3'24
ALK – Opdatering på de første 9 måneder i 2024 og ny strategisk licensaftale med ARS Pharma
SP Group – Præsentation af regnskabet for Q3 2024
Starbreeze Q3´24: PAYDAY 3 keeps improving but player activity remains muted
Implantica, Audiocast with teleconference, Q3'24
View all videos